These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15110763)

  • 1. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
    Owen CP; Ahmed S
    Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
    Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
    Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
    Karkola S; Alho-Richmond S; Wahala K
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
    Fournier D; Poirier D; Mazumdar M; Lin SX
    Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
    Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
    Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
    J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
    Lota RK; Dhanani S; Owen CP; Ahmed S
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
    Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
    J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy.
    Mazumdar M; Fournier D; Zhu DW; Cadot C; Poirier D; Lin SX
    Biochem J; 2009 Dec; 424(3):357-66. PubMed ID: 19929851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
    Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
    Karkola S; Lilienkampf A; Wähälä K
    ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
    Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
    J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
    Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
    Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
    FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
    Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
    J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling Reactions.
    Bérubé M; Poirier D
    Org Lett; 2004 Sep; 6(18):3127-30. PubMed ID: 15330604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
    Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.